healthcare-consulting
(14)
The Company Selling Confidence Before a Medicine Can Be Sold
A drug can work perfectly and still fail to reach patients. OPEN Health built a global consultancy around the awkward middle - the evidence, access, education, and human judgment that turn a scientific result into a confident decision.
The Drug Launch Has Too Many Translators
Citrus Health Group bought its way across the pharmaceutical launch journey. The clever part is not owning every specialty - it is deciding when each one enters the room.
The Company That Sells the Space Between a Handshake and a Headline
For nearly half a century, Strategic Partnerships has worked the overlooked territory between institutions - where a university needs an employer, a nonprofit needs a governor, and a good idea needs someone powerful to notice.
The People Missing From the Drug-Development Meeting
VOZ Advisors built a business around a costly corporate blind spot: medicines are often planned in rooms where the people expected to live with them are missing.
The People Who Know Where the Policy Is Buried
CCR Consulting hires people who have already lived inside the systems its clients are trying to change. The result is a particular kind of consultancy: less crystal ball, more institutional memory with a project plan.
The People Who Read Washington's Fine Print for a Living
A small policy firm built a business around an unglamorous advantage: noticing what changed, explaining why it matters, and doing it before everyone else catches up.
The Deal Closes. Then the People Problem Begins.
Allegrow works in the awkward stretch after the handshake, when two companies have to become one without losing the people, customers, and value that made the deal attractive.
The Best Therapy in the World Still Needs Someone to Say Yes
MEYA Health works in the awkward distance between scientific approval and real-world access - where evidence must become a story that payers, health systems and field teams can actually use.
Cadence and the people missing from the spreadsheet
A healthcare research firm built its edge by reaching people conventional panels struggled to find. Its next challenge is making years of accumulated research easier to use.
Jupiter Capital wants the expert you hire to do the work
The Florida consultancy pairs senior operators with capital-market advice and financial software. Its most pointed promise is simple: the people on the pitch stay on the project.
The nursing-home rulebook is a maze. Zimmet built a business selling the map.
Zimmet started with Medicare cost reports, found a market full of disconnected rules and data, and spent three decades turning that confusion into consulting, software and outsourced clinical work. Its first software win also exposed the flaw that shaped everything after it.
The Consulting Firm You Hire When the Answer Has to Survive Monday Morning
L.E.K. built a global strategy business by staying close to the moments when executives cannot afford a decorative answer - the deal, the launch, the turnaround and the bet on what comes next.
Reveal HealthTech
Reveal HealthTech is a New York-based AI transformation partner for U.S. healthcare and life sciences organizations. Founded in 2023 and incubated by W Health Ventures and 2070 Health, the company pairs clinical expertise with engineering and design to turn AI concepts into deployed products for hospitals, pharma, and digital health innovators. Its flagship products include BioCanvas for clinical trial recruitment, Prism AI for workflow automation, and CareIQ for care coordination. Reveal raised a $7.2M Series A led by Leo Capital in September 2025 and runs teams across the U.S. and Bengaluru, India.
Paul Eccles
Paul Eccles is a molecular biologist turned healthcare strategy consultant who leads Basis Health, the New York-based life sciences division of London-headquartered insight consultancy Basis Global. He joined Basis in September 2022 as Managing Partner after a career spanning Trinity Life Sciences, BluePrint Research Group, Cello Health, and Opinion Health, and has spent more than fifteen years advising pharma, biotech, and clinical incubators on commercialization, licensing, forecasting, and portfolio positioning.